Skip to main content
. 2018 Mar 14;9:462. doi: 10.3389/fmicb.2018.00462

Table 2.

Main molecular evidence of putative pro-oncogenic activity of HERV-derived Env.

Group Env protein Tumor type Molecular mechanism Oncogenic effect References
HERV-W Syncytin-1 (7q21.2) Breast Fusogenicity Cell-cell fusion Bjerregaard et al., 2006
Endometrial Fusogenicity Cell-cell fusion Strick et al., 2007; Strissel et al., 2012
Neuroblastoma Cellular pathway alteration SK3 hyperactivation, excitotoxicity Li et al., 2013
Bladder urothelial cells Unknown Increased cell proliferation and viability Yu et al., 2014
HERV-FRD Syncytin-2 (6p24.1) Breast Ectopic GMC1-induced fusogenicity Cell-cell fusion Liang et al., 2010
Endometrial Fusogenicity Cell-cell fusion Strissel et al., 2012
HERV-K (HML2) Env Breast Stimulation of cellular pathways playing key roles in cancer (EGFR, TGFB1, NF-κB, c-myc, p53, Ras, p-RSK, p-ERK1/2…) Increased cell proliferation, transformation, migration and invasion Zhou et al., 2016; Lemaître et al., 2017
Rec Germ cell Interaction with PLZF abrogates c-myc repression Increased cell proliferation, apoptosis abrogation Denne et al., 2007
Interaction with TZFP and hSGT abrogates the repression of AR and AR-regulated genes (e.g., c-myc) Increased cell proliferation, apoptosis abrogation, stimulation of Rec expression Kaufmann et al., 2010; Hanke et al., 2013a
Np9 Germ cell Interaction with PLZF abrogates c-myc repression Increased cell proliferation, apoptosis abrogation Denne et al., 2007
Interaction with LNX ubiquitin ligase Perturbation of Numb/Notch pathway Armbruester et al., 2004
Interaction with MDM2 ubiquitin ligase Reduced MDM2-mediated proteasomal degradation of p53 Heyne et al., 2015
Lymphoma (EBV-transformed B cells) Interaction with EBV EBNA2 Downregulation of viral promoter activation and transcription factors binding Gross et al., 2011
Leukemia Upregulation of pERK, c-Myc, β-catenin and Notch1 Increased cell proliferation, faster and increased tumor growth Chen et al., 2013

HERV-derived Env proteins for which a specific pro-oncogenic activity and/or a precise effect on cellular transformation have been characterized are included.